fashion -WSS

fashion

author：leisure time 2025-09-06 08:24:56 - browse：945

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： How to make AI work for medicine

WSS

Complete sequence of Y chromosome published for first time

ALS patient reclaims some autonomy thanks to wearable 'robot'

What AAP's gender

NIH tests clinical research in primary care with $30 million program

Coercive sterilizations revealed by STAT prompt outrage

What do new weight loss drugs mean for bariatric surgery?

focus

fashion

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Moderna says combo Covid

Alkermes shareholders re

How to make AI work for medicine

Jerome Adams on the need for new antivirals for Covid

California wildfire smoke linked to 52,000 early deaths, study says

Medicare details structure of new drug price negotiation program

Curing rare childhood diseases will falter unless Congress steps up

United colonoscopy coverage change 'may cost lives,' doctors say

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

focus

Readers discuss the intersection of pregnancy and addiction

Report captures long Covid’s disabling effects and policy challenges

How a symptom of dementia informs our understanding of creativity

'Essentially witchcraft:' A former naturopath takes on the field

AstraZeneca challenges Medicare drug negotiation program

2024 GOP presidential candidates spar over abortion in debate

leisure time

hotspot

knowledge

hotspot